New treatment available for Crohn’s disease
The Therapeutic Goods Administration (TGA) has approved HUMIRA® (adalimumab) for the treatment of adults with moderate to severe Crohn’s disease, which is a serious, chronic, inflammatory disease of the gastrointestinal tract.
People living with Crohn’s can often suffer from diarrhoea, abdominal pain, nausea, weight loss, fever and in some cases, rectal bleeding.
There is no medical or surgical cure for Crohn’s disease and there are few treatment options for patients living with this chronic condition.
According to Professor Peter Gibson of the Department of Medicine at Monash University, Melbourne, “HUMIRA provides another treatment option for those patients suffering from moderate to severe Crohn’s disease who have had an inadequate response to conventional therapies”.
The new medication has been welcomed by the Australian Crohn’s and Colitis Association.
